Impulsive and compulsive behaviors in Parkinson's disease

Antiparkinson therapy can be the primary cause of a range of nonmotor symptoms that include a set of complex disinhibitory psychomotor pathologies and are linked by their repetitive, reward or incentive‐based natures. These behaviors relate to aberrant or excessive dopamine receptor stimulation and...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 24; no. 11; pp. 1561 - 1570
Main Authors Evans, Andrew H., Strafella, Antonio P., Weintraub, Daniel, Stacy, Mark
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.08.2009
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Antiparkinson therapy can be the primary cause of a range of nonmotor symptoms that include a set of complex disinhibitory psychomotor pathologies and are linked by their repetitive, reward or incentive‐based natures. These behaviors relate to aberrant or excessive dopamine receptor stimulation and encompass impulse control disorders (ICDs), punding, and the dopamine dysregulation syndrome (DDS). Common ICDs include pathological gambling, hypersexuality, compulsive eating, and compulsive buying. This review focuses on the phenomenology, epidemiology, and methods to identify and rate these disorders. The management of dopaminergic drug‐related compulsive behaviors is discussed in the light of the current understanding of the neurobiological substrate of these disorders. © 2009 Movement Disorder Society
Bibliography:Potential conflict of interest: Dr Evans has received honoraria from Boehringer Ingelheim, and Novartis. Dr Strafella has no relevant financial disclosures. Dr. Weintraub has served as a consultant, is on an advisory board, and has received grant support from Boehringer Ingelheim. Dr. Stacy serves on the steering committee for the Boehringer Ingelheim sponsored DOMINION trial, and the study principal investigator for the Novartis sponsored nonmotor symptoms of wearing off in PD. He has received honoraria from Novartis, GlaxoSmithKline, Boehringer Ingelheim, and TEVA.
ark:/67375/WNG-89TWBDWS-4
ArticleID:MDS22505
istex:18A9B5CBCB3B8D28AB7EDCDA16D7530FDEDE2F60
This article is part of the journal's online CME program. The CME activity including form, can be found online at http://www.movementdisorders.org/education/journalcme/
http://www.movementdisorders.org/education/journalcme/
This article is part of the journal's online CME program. The CME activity including form, can be found online at
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.22505